GlassScriptPhysician profile
Romer Mosquera
NPI 1790930782
$2,313.26
in general payments reported to CMS, 2019-2025
36 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $49.12 · 2021: $135 · 2022: $180 · 2023: $371 · 2024: $368 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.41 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.11 | 2023-2025 | |
| Cranial Technologies, INC | $220.72 | 2020-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $167.25 | 2025 | Wainua |
| Alexion Pharmaceuticals, INC. | $160.13 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $112.95 | 2019 | |
| Lilly USA, LLC | $110.40 | 2025 | Kisunla |
| Tris Pharma INC | $106.31 | 2021-2025 | Dyanavel Xr |
| Corium, LLC | $94.67 | 2022-2025 | Azstarys |
| Emd Serono, INC. | $76.52 | 2019 | |
| Biogen, INC. | $71.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.01 | 2019-2021 | |
| Genzyme Corporation | $54.84 | 2019 | |
| Phadia US INC. | $53.77 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $52.80 | 2019 | |
| Acadia Pharmaceuticals INC | $52.04 | 2022-2023 | Nuplazid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $45.76 | 2023 | |
| Aprecia Pharmaceuticals, LLC | $45.71 | 2022 | |
| Sanofi Pasteur INC. | $44.56 | 2022-2023 | |
| Acorda Therapeutics, INC | $41.00 | 2019 | |
| Azurity Pharmaceuticals, INC. | $30.67 | 2025 | Zonisade |
| Kowa Pharmaceuticals America, INC. | $28.78 | 2025 | Zoryve |
| Tempus Ai, INC | $25.83 | 2024 | |
| Springworks Therapeutics, INC. | $21.70 | 2025 | Gomekli |
| Argenx US, INC. | $20.86 | 2023 | Vyvgart |
| Genentech USA, INC. | $20.76 | 2021 | |
| Merz Pharmaceuticals, LLC | $20.32 | 2025 | Inbrija, Xeomin |
| Neurelis, INC. | $20.03 | 2021 | |
| Philips North America LLC | $19.62 | 2023 | |
| Hyperfine Operations, INC. | $18.94 | 2025 | Swoop |
| Revance Therapeutics, INC. | $18.06 | 2024 | Daxxify |
| Glaxosmithkline, LLC. | $16.28 | 2020 | |
| Upsher-Smith Laboratories LLC | $14.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.14 | 2019 | |
| Amgen INC. | $12.67 | 2019 | |
| Pfizer INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romer Mosquera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.